Sign up Australia
Proactive Investors - Run By Investors For Investors

Silence Therapeutics on track to be a clinical stage company by year-end

As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements
pipette and petri dish
RNA interference works by 'silencing' genes which are thought to cause diseases

Silence Therapeutics plc (LON:SLN) remains confident that it will kick off its first human clinical trial by the end of the year.

The AIM-quoted company specialises in RNA interference – an experimental type of treatment which aims to treat diseases by suppressing, or ‘silencing’, genes that are thought to cause diseases.

Silence has recruited five senior managers to spearhead the clinical drive.

WATCH: Silence confident of filing first CTA by end of 2018

This is in anticipation of filing Silence's first GalNAc-siRNA CTA (clinical trial authorisation) for the treatment of liver-related iron overload disorders by the end of 2018.

Animal disease models have reinforced that its lead candidate, SLN124, can be effective in the treatment of the genetic conditions.

Data presented over the weekend seemed to back this up, with Silence’s drug discovery project leader Dr Ute Schaeper describing the drug as a “promising candidate”.

A second programme in alcohol use disorder is set for a CTA filing mid-2019, potentially through a partnership.

On lookout for new CEO

It will be doing this without its long-serving chief executive Ali Mortazavi who stepped down from his role earlier this month (June).

Silence’s chair, Annalisa Jenkins, is filling the position temporarily until a permanent successor is found. Her job, and that of the new boss, will be to build on Mortazavi’s work.

In particular, they will be tasked with defending the company’s intellectual property.

Silence believes that a number of companies, including US giant Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), have been using technology covered by its patents in drugs that silence genes and may be fundamental in the war against cancer.

READ: Silence launches another patent battle with Alnylam

The firm has, over the past year, sought to shore up the patent protection around what it calls a “foundational innovation” that is core to the emerging RNAi industry.

“Silence believes that these newly granted claims are relevant to third-party RNAi medicines and that its foundational IP is essential for the clinical and commercial viability of the RNAi field.”

Silence revealed earlier this year that litigation with Alnylam is “progressing” and it expects a trial to start in the UK at the beginning of December.

Plenty of cash…

At the end of 2017, the company had £43mln of cash in the bank compared to £30mln this time last year.

One of the primary reasons for the jump in the net cash balance was Silence’s investment in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).

READ: Silence has £43mln in the bank after Arrowhead disposal

At the end of 2016, Silence spent £8.3mln (US$11.3mln) to take a 10% stake in Arrowhead with the view to some form of strategic transaction.

By March 2017, Silence said it had become clear that such a transaction would not be possible, so it started to close its position in Arrowhead.

The AIM-quoted group has now completed the sale of its entire stake, generating net sale proceeds of US$24.7mln, a net profit of US$13.4mln.

Some of that cash will be used to fund the aforementioned clinical trials, while it also wants to invest in developing a “deep pre-clinical pipeline”.

“Well-positioned” for 2018

“Silence [has] demonstrated that it is now has a powerful, reproducible and modular GalNAc-siRNA platform that can rapidly and safely be used to specifically and effectively silence any disease-associated target gene in hepatocytes,” said now ex-CEO Ali Mortazavi.

“With £43mln of cash at the start of 2018, Silence is well positioned to further develop its existing pipeline, as well as adding significant new targets, some incorporating next generation technology.

“At the same time, we are actively looking to partner our platform and programmes, and to enter into both commercial and academic collaborations, strengthening our balance sheet and widening our portfolio.”

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use